Celularity

placenta-derived cell therapies, allogeneic cellular medicine, advanced biomaterials

replacementreplacingcell therapy

celularity.com·New York City, New York, United States·Public

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-3QRH

Summary · Eternal Search editorial

Celularity placenta-derived cell therapies, allogeneic cellular medicine, advanced biomaterials

Celularity Inc. is an innovative regenerative and cellular medicine company developing and commercializing advanced biomaterial products and allogeneic cryopreserved cell therapies. Its products are derived from the postpartum placenta and target age-related diseases. The company highlights off-the-shelf allogeneic cellular therapies, including MLASCs, Natural Killer cells, and engineered T cells including CAR-T cells.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite14

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Celularity — Translational · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…

Source: Deterministic

At a glance

Webcelularity.com

HQNew York City, New York, United States

StagePublic

Publications

14 on file

012025Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomised, Double-Blind, Placebo-Controlled Trial.International wound journal→022025Senescence, NK cells, and cancer: navigating the crossroads of aging and disease.Frontiers in immunology→032025The Use of Flowable Decellularized Human Placental Connective Tissue Matrix in Alveolar Ridge Preservation: A Split-Mouth Pilot Study.Dentistry journal→042024Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T.Journal for immunotherapy of cancer→052023Characterization of human placenta-derived exosome (pExo) as a potential osteoarthritis disease modifying therapeutic.Arthritis research & therapy→062023Placental-Derived Biomaterials and Their Application to Wound Healing: A Review.Bioengineering (Basel, Switzerland)→072023Characterization of CRISPR/Cas9-edited human placental allogenic stromal cells with low tissue factor expression and reduced thrombotic effects.Cytotherapy→082023An in vitro comparison of human corneal epithelial cell activity and inflammatory response on differently designed ocular amniotic membranes and a clinical case study.Journal of biomedical materials research. Part B, Applied biomaterials→092023A tri-layer decellularized, dehydrated human amniotic membrane scaffold supports the cellular functions of human tenocytes in vitro.Journal of materials science. Materials in medicine→102022Human placental hematopoietic stem cell-derived natural killer cells (CYNK) recognize and eliminate influenza A virus-infected cells.Frontiers in immunology→112022A decellularized flowable placental connective tissue matrix supports cellular functions of human tenocytes in vitro.Journal of experimental orthopaedics→122022Human placental hematopoietic stem cell derived natural killer cells (CYNK-001) mediate protection against influenza a viral infection.Human vaccines & immunotherapeutics→132021Phase 2a randomized controlled study investigating the safety and efficacy of PDA-002 in diabetic peripheral neuropathy.Journal of the peripheral nervous system : JPNS→142021CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy.Journal for immunotherapy of cancer→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Celularity

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.